Biodexa Pharmaceuticals (NASDAQ:BDRX) is reaching for the stars in today’s trading session following an insightful development on one of its brain cancer treatments.

The company unveiled intriguing results from early trials of MTX110, showcasing promising outcomes for brain cancer patients, including an extension in survival rates.

During a Phase 1 trial, individuals administered MTX110 experienced a median survival rate of 26 months, a stark contrast to the typical 10-month survival rate.

In response to this groundbreaking news, Biodexa Pharmaceuticals expressed optimism about the potential of MTX110 to prolong patient life. The company’s innovative delivery method also offers the possibility of reducing adverse side effects, a crucial factor in treating cancers with high mortality rates.

“Biodexa is hopeful MTX110 could potentially help extend patient life, offering much-needed hope to patients and their families. The company’s delivery method may also help prevent full-body exposure, which could minimize negative side effects. For cancers with such high mortality rates, any amount of extra time with a better quality of life is groundbreaking.”

BDRX Stock Movement Today

Thursday has seen a flurry of activity surrounding BDRX stock, with over 67 million shares changing hands, significantly surpassing its daily average trading volume of approximately 628,000 shares.

As the morning unfolds, BDRX stock is surging by a remarkable 106%.

If you are hungry for more digestible stock market news for today, there’s a feast waiting for you below!

Dive into the latest updates about stocks like Xilio Therapeutics (NASDAQ:XLO), Sega Sammy (OTCMKTS:SGAMY), and AMC Entertainment (NYSE:AMC) to stay ahead of the pack!

More Stock Market News for Thursday

About Penny Stocks and Low-Volume Stocks: With exceedingly rare exceptions, InvestorPlace refrains from discussing companies with a market cap below $100 million or those trading less than 100,000 shares daily. This caution stems from the predatory nature of penny stocks, often exploited by unscrupulous actors. In the few instances we cover low-volume stocks, our writers solemnly disclose this fact, alerting readers to the associated risks.

Read More: Unraveling the Mysteries of Penny Stocks

As of the publication date, William White has no direct or indirect positions in the securities discussed. The opinions presented here are solely those of the author and conform to the guidelines set by InvestorPlace.com.